KEYTRUDA® (pembrolizumab) KEYNOTE-355 clinical data presentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

PDF, 1.80 MB

The KEYNOTE-355 study explores KEYTRUDA (pembrolizumab) in combination with chemotherapy for patients with locally recurrent unresectable or metastatic triple-negative breast cancer, whose tumours express PD-L1 with a CPS ≥10 and who have not received prior chemotherapy for metastatic disease.

CPS = Combined Positive Score; PD-L1 = Programmed Death Ligand 1

Click on the resource to download.

More information about KEYTRUDA® (pembrolizumab) in triple-negative breast cancer (TNBC)

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) 
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website.